China Pharma (CPHI) Competitors $1.84 +0.10 (+5.44%) As of 07/3/2025 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CPHI vs. NNVC, BCAB, SNYR, CMMB, ALXO, VYNE, OVID, ELEV, FNCH, and FGENShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include NanoViricides (NNVC), BioAtla (BCAB), Synergy CHC (SNYR), Chemomab Therapeutics (CMMB), ALX Oncology (ALXO), VYNE Therapeutics (VYNE), Ovid Therapeutics (OVID), Elevation Oncology (ELEV), Finch Therapeutics Group (FNCH), and FibroGen (FGEN). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. Its Competitors NanoViricides BioAtla Synergy CHC Chemomab Therapeutics ALX Oncology VYNE Therapeutics Ovid Therapeutics Elevation Oncology Finch Therapeutics Group FibroGen China Pharma (NYSE:CPHI) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Does the media prefer CPHI or NNVC? In the previous week, China Pharma and China Pharma both had 1 articles in the media. NanoViricides' average media sentiment score of 1.00 beat China Pharma's score of 0.34 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CPHI or NNVC? China Pharma has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Which has stronger earnings and valuation, CPHI or NNVC? China Pharma has higher revenue and earnings than NanoViricides. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina Pharma$4.30M1.40-$3.08MN/AN/ANanoViricidesN/AN/A-$8.29M-$0.70-2.00 Is CPHI or NNVC more profitable? NanoViricides has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets China Pharma-85.56% -63.93% -31.42% NanoViricides N/A -87.90%-78.69% Do insiders and institutionals have more ownership in CPHI or NNVC? 10.3% of NanoViricides shares are owned by institutional investors. 17.3% of China Pharma shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryChina Pharma beats NanoViricides on 5 of the 9 factors compared between the two stocks. Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$6.00M$790.73M$5.53B$20.73BDividend YieldN/A4.84%5.24%3.72%P/E RatioN/A1.1327.5228.09Price / Sales1.40226.97421.0238.31Price / CashN/A23.4436.8922.53Price / Book2.636.298.044.58Net Income-$3.08M-$27.73M$3.18B$986.06M7 Day Performance0.77%1.21%2.82%2.79%1 Month Performance11.31%9.47%3.70%5.42%1 Year Performance-93.04%7.77%35.41%14.63% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina Pharma0.3658 of 5 stars$1.84+5.4%N/A-93.0%$6.00M$4.30M0.00250NNVCNanoViricides1.1385 of 5 stars$1.40flatN/A-20.5%$22.50MN/A-1.9420Gap DownBCABBioAtla2.581 of 5 stars$0.40+3.1%$5.00+1,162.6%-73.4%$22.43M$11M-0.3260News CoverageGap DownSNYRSynergy CHC3.7794 of 5 stars$2.85+17.3%$10.00+250.9%N/A$22.34M$34.83M0.0040Gap UpHigh Trading VolumeCMMBChemomab Therapeutics2.9217 of 5 stars$1.16-0.9%$8.50+632.8%+22.0%$22.06MN/A-1.5320ALXOALX Oncology2.6621 of 5 stars$0.42+2.3%$3.30+695.0%-91.6%$21.67MN/A-0.1740Positive NewsGap UpVYNEVYNE Therapeutics3.1172 of 5 stars$1.65+16.2%$6.25+278.8%-24.6%$21.60M$500K-1.6730Positive NewsHigh Trading VolumeOVIDOvid Therapeutics4.4625 of 5 stars$0.33+9.2%$3.13+847.3%-54.2%$21.48M$570K-0.9460High Trading VolumeELEVElevation Oncology1.9507 of 5 stars$0.37+1.3%$3.39+822.3%-85.7%$21.46MN/A-0.4540FNCHFinch Therapeutics Group0.3957 of 5 stars$13.20flatN/A+921.5%$21.20M$110K-1.50190FGENFibroGen4.7136 of 5 stars$5.30+1.5%$250.00+4,617.0%-67.1%$21.10M$29.62M-2.12570Positive NewsInsider TradeGap Up Related Companies and Tools Related Companies NanoViricides Competitors BioAtla Competitors Synergy CHC Competitors Chemomab Therapeutics Competitors ALX Oncology Competitors VYNE Therapeutics Competitors Ovid Therapeutics Competitors Elevation Oncology Competitors Finch Therapeutics Group Competitors FibroGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPHI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
